OBJECTIVES: Dupuytren’s disease (DD) is a connective tissue disorder leading to contractures. The use of Collagenase Clostridium histolyticum (CCH) as a potential minimally-invasive, non-surgical option to treat DD has been approved. The goal was to assess the quality of life of patients with DD and treated with CCH in Valencian Community Hospitals.

METHODS: Patients aged 18 years and over, with DD and active extension deficit (AED) ≥20° in the metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joint, with a palpable cord and having been treated or going to be treated with CCH were included in this prospective observational multicenter study. Change in hand function were assessed combining physical measures (i.e, goniometry) and QuickDASH questionnaires at 30 days post injection visit. We performed a logistic regression to describe the improvement of QuickDASH (10% increment vs baseline) adjusted by demographic variables and functional variables.

RESULTS: Overall, 48 patients (51 joints) received one CCH injection, and 46 patients (49 joints) completed the study. Patients had 66 years, 84% men, 75% of patients without DD family story and 82% naïve. QuickDASH score decreased from 26.80 (21.71) to 17.92 (18.05) (p<0.01). AED score decreased from 27.49 (22.15) to 0.82 (3.44) for MCP, and 29.53 (25.63) to 6.14 (11.80) for PIP. The best logistic model included (level of studies categorized [OR: 0.11 (CI95% 0.02 to 0.56)], change in the mobility of the extension of the PIP and the MCP joint [OR: 1.01 (CI95% 0.95 to 1.07) and OR: 0.96 (CI95% 0.90 to 1.03)], and implicated finger [OR: 0.16 with CI95% (0.02 to 1.05)].

CONCLUSIONS: Treatment with CCH for DD is an effective treatment in the short term and able to increase quality of life. The educational level seems to work as an independent predictor of the surgical improvement of quality of life improvement.